The Australian Financial Review has spoken to several of Dixon's 4,800 clients, and viewed the portfolios of three former clients. In each case they had been steered by their advisers to invest more than half their savings in funds managed by Dixon. The funds charged above-market fees yet delivered below-market returns

For the record, to be absolutely clear, as advised to APRA in writing by counsel, this author has never been a director of any company when it was called “Trio”. Assertions to contrary are false, a factual mistake by APRA more interested in administrative convenience than fact, which remains uncorrected and potentially defamatory.

Millhouse Inc Plc is targeting high quality financial services acquisitions for consolidation. We believe that the consolidation phase will be followed by a period where demand will exceed supply. Millhouse Inc Plc is now preparing for a London listing on GXG where improved liquidity and progress in the business plan suggest an attractive debut.

David Millhouse's investment and asset management organisation, MillhouseIAG, continues to help bring some of the world's most vital and innovative medical and health technologies to market - yet its work remains hardly recognised in Australia

Top performing non-equity funds

MillhouseIAG's Private Equity Fund has taken a different track, investing in two of its wholesale private equity trusts

There's a lot to love about Brisbane but it could be even better

David Millhouse defines why he chose Brisbane to do business

Representatives of three German investee businesses of Brisbane-based MillhouseIAG visited Australia in August to brief funds investors on their activities.

MillhouseIAG Limited has returned in excess of 24 per cent per year net of fees on each of its private equity funds in their first two years and expects even better performance from the third year - currently being audited - according to cheif executive David Millhouse. Mr Millhouse is the founder of the Brisbane based business that operates across a range of business advisory and funds management areas.

Australian biotechnology companies need to look for early stage intellectual property partners before seeking venture capital money, according to the founder of one international private equity and venture capital firm

UniQuest Limited, the University of Queensland's contract research and marketing company, has doubled its annual sales figure for the fourth year in a row

David Millhouse discusses the importance of innovation in business, and of an entrepreneurial spirit for commercial success

A former researcher, salesman and PR man is working to maximise the value of Queensland University's research

Australia's leading technology broker, that is the title earned by UniQuest Ltd, a fledgling company set up to market the "brain and machine power" of Queensland University

Uniquest LTD began trading in 1984 to perform the management functions of research contracting, consulting and testing services and with the aim of developing new projects and new companies. It has become recognised as the leading “technology broker” in the country and has already helped create and float two high-technology companies - Queensland Science an Technology Ltd and the biochemical and bio-medical company Qlone Ltd.